Finally, there is an urgent need for FTLD-TDP/ALS-specific biomarkers [30], and ELISAs that are able to reliably measure CSF and/or plasma levels of TDP-43 will be useful not only for diagnosis, but also for monitoring responses to disease modifying therapies for FTLD-TDP, ALS and other TDP-43 proteinopathies [31]. This evidence concerns the gene TARDBP and proteostasis deficiencies.